Exchange: NYSE·Updated 07:59 PM EST

STE News

News
all
press releases
Buy 3 Medical Device Stocks for a Stable Portfolio With Solid Upside
ISRG, STE and PLSE offer exposure to AI-enabled medical devices, rising healthcare demand and potential price upside, making them stocks to watch in 2026.
Zacks
Buy 3 Medical Device Stocks for a Stable Portfolio With Solid Upside
ISRG, STE and PLSE offer exposure to AI-enabled medical devices, rising healthcare demand and potential price upside, making them stocks to watch in 2026.
Zacks
More News
STERIS plc (NYSE:STE - Get Free Report) VP Julia Madsen sold 2,046 shares of the stock in a transaction on Friday, November 13th. The stock was sold at an average price of $260.00, for a total value of $531,960.00. Following the sale, the vice president owned 10,211 shares of the company's stock...
MarketBeat
Steris (NYSE:STE) has outperformed the market over the past 10 years by 1.87% on an annualized basis producing an average annual return of 14.74%. Currently, Steris has a market capitalization of $25.67 billion. Buyingread more...
Benzinga
STERIS beats Q2 fiscal 2027 earnings and revenue estimates, fueled by strong segment growth and margin gains, and raises its full-year adjusted EPS outlook.
Zacks
(RTTNews) - STERIS plc (STE) revealed earnings for its second quarter that Increases, from the same period last year...
Nasdaq News: Markets
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Steris (STE) delivered earnings and revenue surprises of +10.11% and +1.54%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.
Zacks
GMED and STE offer exposure to healthcare technology growth, with projected 2026 EPS gains, attractive valuations and innovations in essential medical services.
Zacks
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.
Zacks

Advertisement|Remove ads.